Kyntra Bio, Inc.
KYNB
$7.91
-$0.13-1.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -209.35% | 36.47% | -59.27% | 774.80% | 35.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -209.35% | 36.47% | -59.27% | 774.80% | 35.07% |
| Cost of Revenue | 14.67% | 23.81% | -65.89% | -94.22% | -81.69% |
| Gross Profit | -80.29% | -18.63% | 66.98% | 99.62% | 85.39% |
| SG&A Expenses | 31.30% | -27.68% | -13.13% | -43.44% | -52.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.69% | 0.01% | -51.44% | -77.97% | -72.56% |
| Operating Income | -50.64% | 6.75% | 50.54% | 81.57% | 74.88% |
| Income Before Tax | 186.92% | 9.74% | -68.65% | 72.78% | 70.92% |
| Income Tax Expenses | 98.91% | -- | -100.00% | -- | 67.26% |
| Earnings from Continuing Operations | 187.51% | 9.75% | -68.61% | 72.78% | 70.95% |
| Earnings from Discontinued Operations | -- | -100.31% | -98.54% | 585.02% | -80.73% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 257.49% | -427.61% | -179.08% | 1,274.41% | 51.09% |
| EBIT | -50.64% | 6.75% | 50.54% | 81.57% | 74.88% |
| EBITDA | -53.50% | 4.69% | 49.92% | 81.77% | 74.93% |
| EPS Basic | 257.26% | -426.90% | -178.83% | 1,267.73% | 51.68% |
| Normalized Basic EPS | -41.45% | 9.39% | 49.52% | 78.19% | 72.10% |
| EPS Diluted | 257.26% | -426.90% | -178.83% | 1,267.73% | 51.68% |
| Normalized Diluted EPS | -41.45% | 9.39% | 49.52% | 78.19% | 72.10% |
| Average Basic Shares Outstanding | 0.15% | 0.22% | 0.32% | 0.57% | 1.23% |
| Average Diluted Shares Outstanding | 0.15% | 0.22% | 0.32% | 0.57% | 1.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |